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P ediatric cardiomyopathies, although rare inthe general population, are associated withsigniﬁcant morbidity, mortality, and cost (1).
Much of our knowledge of the epidemiology and out-
comes of these diseases can be traced to the 2 large,
prospective, population-based studies that began in
late 1980s and early 1990s: the Pediatric Cardiomyop-
athy Registry from North America and the National
Australian Childhood Cardiomyopathy Study from
Australia (2–5). The National Australian Childhood
Cardiomyopathy Study was initiated in 1987 and
enrolled 301 children diagnosed with cardiomyopathy
at <10 years of age (2). With its strict inclusion criteria
and, most importantly, robust follow-up, the results
from this cohort have provided valuable insights
into the epidemiology and long-term outcomes (3,6).
Its North American counterpart, the Pediatric Car-
diomyopathy Registry, enrolled approximately 3,500
children between 1991 and 2012 in both prospective
and retrospective fashion (5,7). Although they are
not natural history studies per se, studies from these
Australian and North American pediatric cardiomyop-
athy registries allow for examination of the evolution
of disease processes over time while minimizing the
variability of diagnosis and treatment effect associ-
ated with smaller studies and single-center reports.
In this issue of the Journal, Bharucha et al.
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disclose.understanding of the incidence and risk factors for
sudden cardiac death (SCD) in this population. Thestudy team investigated the incidence of SCD with 4
of the major cardiomyopathy subtypes encountered
in children: dilated cardiomyopathy (DCM), hyper-
trophic cardiomyopathy (HCM), restrictive cardio-
myopathy (RCM), and left ventricular noncompaction
(LVNC). From this analysis, risk factors for SCD were
determined. With a median follow-up of just over 11
years, the cumulative incidence of SCD for the entire
cohort was 5.5%; when stratiﬁed by cardiomyopathy
subtype, statistically signiﬁcant differences in SCD
incidence emerged: 5% for DCM, 6% for HCM, 12% for
RCM, and 23% for LVNC (p ¼ 0.007). Risk factors for
SCD in patients with DCM included older age at
diagnosis, familial DCM, and lower fractional short-
ening z-score. In patients with HCM, the sole risk
factor for SCD was higher left ventricular posterior
wall thickness z-score. No statistically signiﬁcant risk
factors for SCD were identiﬁed in LVNC, and the low
incidence of SCD (1 patient) prevented analysis of risk
factors in patients with RCM. Overall, the low event
rates observed in this study precluded multivariable
analysis.
Several noteworthy ﬁndings emerge from this
study. Although SCD is unquestionably a devastating
event, it occurs uncommonly in most pediatric pa-
tients with cardiomyopathy. This is generally in
keeping with the results of previous studies of SCD in
pediatric patients with cardiomyopathy at an inci-
dence of approximately 5% or less (9,10), although
this study is noteworthy for the completeness and
duration of its follow-up. Understanding the timing
of SCD is also of great importance, which is another
strength of this study. In the present study by
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diomyopathy phenotypes occurred within the ﬁrst 3
years of diagnosis, but for patients with DCM and
HCM, an ongoing risk of SCD was observed several
years beyond diagnosis. Unfortunately, further de-
tails are not provided regarding clinical characteris-
tics of these patients who experienced relatively
“late” events, which could be helpful in guiding cli-
nicians on the appropriate amount of clinical scrutiny
to place on individual patients who are being fol-
lowed several years subsequent to the time of initial
diagnosis.
No patients with echocardiographic normalization
of left ventricular shortening fraction experienced
SCD. This ﬁnding was also observed in the recent
series of LVNC patients from Texas Children’s Hos-
pital (11). Echocardiographic normalization appears
to occur with substantial frequency in pediatric pa-
tients with cardiomyopathy, depending on the etiol-
ogy. In a separate report from the National Australian
Childhood Cardiomyopathy Study, nearly 70% of
patients who remained free from transplantation
attained normalization of ventricular function at
15 years of follow-up; for the entire cohort, the rate of
normalization was approximately 33% (3). A similar
study from the Pediatric Cardiomyopathy Registry (7)
limited to patients with idiopathic DCM and with
shorter follow-up, demonstrated an approximately
20% incidence of normalization. It is important to
note that in the latter study, 9% of the patients with
normalization of function later died or underwent
transplantation, suggesting that the risk of signiﬁcant
events may persist even after echocardiographic
recovery.
The higher incidence of SCD in patients with RCM
relative to DCM and HCM must be interpreted in the
context of a low total number of events (1 event) in
a small patient population (8 patients). Previous
reports have also revealed poor outcomes, often
related to sudden, unpredictable events in this sub-
group, leading many practitioners to consider trans-
plantation shortly after the diagnosis of RCM is made
(12). The relatively high incidence of SCD in patients
with LVNC (23%) observed in the present study by
Bharucha et al. (8) is surprising, however. This con-
trasts with a recent large, single-center series consist-
ing of 242 patients with LVNC, in which the incidence
of SCD was much lower at 6.2% (11). The marked
discrepancy in the incidence of SCD between study
populations suggests substantial differences in the
clinical characteristics, including potential genetic
differences, of the patients studied, and these differ-
ences likely become magniﬁed when dealing with
events (such as SCD) that have low rates of occurrence.The SCD events reported in the present study
should be regarded in the setting of current heart
failure management strategies, which are constantly
changing and evolving based upon accumulated
experience and new data. It is impossible to know
how the observed incidence of sudden death would
be altered by different management strategies of
medication utilization, implantable cardioverter-
deﬁbrillators (ICDs), and heart transplantation.
ICDs were placed in a small proportion (6.6%)
of patients. Approximately 30% of those patients
received what were deemed to be “appropriate”
therapy from the device. The authors performed a
competing risk analysis, segregating patients into the
mutually exclusive categories of heart failure death/
transplantation, ICD implantation, SCD, and alive, to
estimate the effect of ICD utilization on SCD inci-
dence. However, the effect of medical therapy on SCD
incidence is unclear, and given the known variability
between centers in the utilization of speciﬁc classes
of medication for pediatric heart failure (13), it is
plausible that this also affected the incidence of
SCD reported in this study.
There are several important questions that remain
unanswered regarding SCD in pediatric cardiomyop-
athy. Can the risk of SCD be reduced without
increasing morbidity in an already vulnerable patient
population? Are ICDs the best modality for reducing
SCD in children with cardiomyopathy? Our colleagues
in adult medicine have already proceeded through
this exercise. From the proof of pharmacological
failure of arrhythmia suppression in the 1980s, to the
ICD trials of the late 1990s and early 2000s, the sur-
vival beneﬁt of primary prevention ICDs in carefully
selected patients with cardiomyopathy rests on a
relatively ﬁrm scientiﬁc foundation. In pediatrics,
however, we are faced with the conundrum of rare
diagnoses with low event rates, which places chal-
lenges on conducting clinical trials. The technical
challenges and higher rates of complications of ICDs
in children (14) prevent simple application of adult
therapies to the pediatric population and reinforce
the concept that children are not merely small adults.
Bharucha et al. (8) correctly point out that their study
is not intended to identify which patients would
beneﬁt from ICD implantation, but merely serves as a
starting point for further studies of the issue. Based
on the current study and previous work, we now have
a reasonable estimate for the incidence of SCD in
children with cardiomyopathy, with identiﬁcation
of certain risk factors. Moving forward, the next
challenge for our ﬁeld is to carefully identify
the circumstances of SCD in these children, and strive
to mitigate the risk factors that may lead to such
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2313circumstances, whether it be through ICDs, improved
medical therapy, selective use of transplantation or
mechanical circulatory support, or a combination
thereof.
The rigorous study of relatively rare conditions
continues to present an ongoing challenge in pediatric
cardiovascular medicine. Thus, not only is this study
very important in contributing to our understanding of
a speciﬁc cardiac event in a speciﬁc population, but
studies such as these are fundamental to our under-
standing of pediatric cardiovascular diseases. Large,
prospective, and population-based studies of rare
conditions are absolutely necessary to truly under-
stand the disease and the population. However,
these studies are expensive, and do not involve
“breakthrough therapies” that will generate an
enormous ﬁnancial return on investment. Moreover,they take time and important results will often not
be evident until well beyond the typical duration of
most grants. The genesis of this study was over 25
years ago, and although our knowledge of these
diseases has increased dramatically as a result, in
many ways our understanding of them is just
beginning. The proliferation of substantial contri-
butions from the Australian and North American
pediatric cardiomyopathy registries to the literature
in recent years is ongoing proof of the foresight of
those who initiated these studies a generation ago.
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